Lyell Immunopharma to acquire ImmPACT Bio, cut top programs

Katherine Lewin

News Reporter

Lyell Immunopharma is discontinuing several programs and acquiring CAR-T biotech ImmPACT Bio and its suite of clinical-stage candidates for $30 million …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Lyell Immunopharma to acquire ImmPACT Bio, cut top programs

Katherine Lewin

News Reporter

Sign up to read this article for free.

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

Elucida Oncology, seeking foothold in ADCs, shutters due to 'lack of funding'

Chinook alums reunite following exit to Novartis; The first board appointment for Recursion’s Chris Gibson

Tyra's stock dips as it gives first look in challenge to J&J’s bladder cancer drug Balversa

Septerna bags $288M upsized IPO for GPCR drugs

Bristol Myers, Ideaya tout data in solid tumors with certain genetic mutations

IDEAYA Biosciences: Targeting unmet market needs with precision oncology

Lyell Im­munophar­ma to ac­quire Imm­PACT Bio, cut top pro­grams

News Reporter

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

Lyell Immunopharma to acquire ImmPACT Bio, cut top programs